|1.||Galindo-Tovar, Alejandro: 3 articles (07/2014 - 01/2009)|
|2.||Kaumann, Alberto J: 3 articles (07/2014 - 01/2009)|
|3.||Sahu, Abhiram: 2 articles (07/2010 - 08/2002)|
|4.||Escudero, Elisa: 2 articles (11/2009 - 01/2009)|
|5.||Engel, Andreas: 1 article (07/2014)|
|6.||Gillette, Katherine T: 1 article (07/2014)|
|7.||Berk, Emanuel: 1 article (07/2014)|
|8.||Christ, Torsten: 1 article (07/2014)|
|9.||Molenaar, Peter: 1 article (07/2014)|
|10.||Ravens, Ursula: 1 article (07/2014)|
01/01/2009 - "5-HT-evoked sinoatrial tachycardia did not fade and was not potentiated by cilostamide (300 nmol.L(-1)) or rolipram (1 micromol.L(-1)). "
02/01/2008 - "Both rolipram (1 microM) and cilostamide (300 nM) caused transient sinoatrial tachycardia but neither enhanced the chronotropic potency of (-)-adrenaline. "
11/01/2009 - "At high concentrations (10-30 microM), the PDE1, PDE3 and PDE5 inhibitors 8-methoxymethyl-3-isobutyl-1-methylxanthine, cilostamide and sildenafil, respectively, caused marginal tachycardia but did not significantly change the chronotropic potency of (-)-noradrenaline. "
|2.||Body Weight (Weight, Body)
07/19/2010 - "We have previously demonstrated that leptin stimulates phosphodiesterase-3B (PDE3B) activity in the hypothalamus, and PDE3 inhibitor cilostamide reverses anorectic and body weight reducing effects of leptin. "
08/01/2002 - "Using male Sprague-Dawley rats implanted with third intracerebroventricular (ICV) cannulae, we found that cilostamide, a phosphodiesterase 3 (PDE3) inhibitor, (i) reversed the established effects of leptin on food intake and body weight, (ii) blocked, at the hypothalamic level, the leptin-induced tyrosine phosphorylation of signal transducer and activator of transcription 3 (Stat3) and (iii) blocked the DNA binding of p-Stat3. "
08/01/2012 - "The hypoxia-induced hPASMC proliferation was completely prevented by the addition of 8-Br-cAMP, forskolin, or cilostamide. "
01/01/2005 - "Furthermore, during exposure to hypoxia for 13 days, Wistar rats were treated with iloprost, rolipram, cilostamide, or combinations of these agents. "
05/01/2000 - "These results indicate that cilostamide suppresses intimal hyperplasia both in the single- and double-injury models of rat, presumably by inhibiting proliferation rather than migration of VSMC. "
05/01/2000 - "The effects of cilostamide, a cyclic nucleotide phosphodiesterase 3 (PDE3) selective inhibitor, on vascular intimal hyperplasia were evaluated using a single-balloon injury model and a double-injury model in which the rat common carotid artery was subjected to a second injury at a site injured 14 days previously. "
05/01/2000 - "Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model."
05/01/2000 - "Oral administration of cilostamide for 2 weeks after the second injury suppressed intimal hyperplasia in the double-injury model (30 mg kg(-1) bid, 83% inhibition in terms of the IM ratio, P<0.05; 100 mg kg(-1) bid, 69% inhibition, P<0.05). "
|4.||Phosphodiesterase 5 Inhibitors
|5.||Type 4 Cyclic Nucleotide Phosphodiesterases
|6.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)